Dearborn Partners LLC Sells 1,756 Shares of Stryker Co. (NYSE:SYK)

Dearborn Partners LLC decreased its stake in Stryker Co. (NYSE:SYK - Free Report) by 1.7% in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 104,311 shares of the medical technology company's stock after selling 1,756 shares during the quarter. Stryker accounts for about 1.6% of Dearborn Partners LLC's investment portfolio, making the stock its 23rd largest holding. Dearborn Partners LLC's holdings in Stryker were worth $37,557,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors have also recently bought and sold shares of SYK. Leavell Investment Management Inc. boosted its position in Stryker by 24.4% during the third quarter. Leavell Investment Management Inc. now owns 1,111 shares of the medical technology company's stock valued at $402,000 after purchasing an additional 218 shares during the last quarter. Verdence Capital Advisors LLC boosted its position in Stryker by 19.8% during the third quarter. Verdence Capital Advisors LLC now owns 1,621 shares of the medical technology company's stock valued at $586,000 after purchasing an additional 268 shares during the last quarter. Assetmark Inc. boosted its position in Stryker by 30.7% during the third quarter. Assetmark Inc. now owns 1,013 shares of the medical technology company's stock valued at $366,000 after purchasing an additional 238 shares during the last quarter. Atria Investments Inc boosted its position in Stryker by 11.2% during the third quarter. Atria Investments Inc now owns 23,722 shares of the medical technology company's stock valued at $8,570,000 after purchasing an additional 2,383 shares during the last quarter. Finally, XML Financial LLC boosted its position in Stryker by 7.1% during the third quarter. XML Financial LLC now owns 3,100 shares of the medical technology company's stock valued at $1,120,000 after purchasing an additional 205 shares during the last quarter. Hedge funds and other institutional investors own 77.09% of the company's stock.

Remove Ads

Stryker Stock Performance

SYK stock traded down $0.09 during midday trading on Wednesday, reaching $365.20. 979,092 shares of the company were exchanged, compared to its average volume of 1,214,340. The business has a 50-day moving average price of $382.70 and a two-hundred day moving average price of $373.40. The firm has a market capitalization of $139.35 billion, a price-to-earnings ratio of 46.98, a price-to-earnings-growth ratio of 2.93 and a beta of 0.95. Stryker Co. has a one year low of $314.93 and a one year high of $406.19. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.95 and a quick ratio of 1.32.

Stryker (NYSE:SYK - Get Free Report) last announced its earnings results on Tuesday, January 28th. The medical technology company reported $4.01 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $3.87 by $0.14. Stryker had a net margin of 13.25% and a return on equity of 23.58%. During the same period in the previous year, the firm earned $3.46 earnings per share. Equities research analysts forecast that Stryker Co. will post 13.47 EPS for the current year.

Stryker Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, April 30th. Investors of record on Monday, March 31st will be issued a $0.84 dividend. The ex-dividend date is Monday, March 31st. This represents a $3.36 dividend on an annualized basis and a yield of 0.92%. Stryker's dividend payout ratio (DPR) is presently 43.30%.

Insider Buying and Selling

In related news, Director Ronda E. Stryker sold 201,392 shares of the business's stock in a transaction on Friday, January 31st. The shares were sold at an average price of $392.24, for a total value of $78,993,998.08. Following the transaction, the director now owns 3,642,075 shares in the company, valued at $1,428,567,498. The trade was a 5.24 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Allan C. Golston sold 2,458 shares of the company's stock in a transaction dated Tuesday, February 18th. The shares were sold at an average price of $383.07, for a total transaction of $941,586.06. Following the transaction, the director now owns 14,895 shares in the company, valued at $5,705,827.65. This represents a 14.16 % decrease in their position. The disclosure for this sale can be found here. 5.90% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

Several research firms have weighed in on SYK. JPMorgan Chase & Co. raised their target price on Stryker from $420.00 to $445.00 and gave the company an "overweight" rating in a report on Wednesday, January 29th. Truist Financial raised their target price on Stryker from $409.00 to $413.00 and gave the company a "hold" rating in a report on Thursday, January 30th. JMP Securities restated a "market perform" rating on shares of Stryker in a report on Tuesday, February 18th. The Goldman Sachs Group set a $422.00 target price on shares of Stryker in a research report on Tuesday, March 4th. Finally, Needham & Company LLC restated a "buy" rating and issued a $442.00 price target on shares of Stryker in a research report on Wednesday, January 29th. Five equities research analysts have rated the stock with a hold rating and sixteen have issued a buy rating to the company. Based on data from MarketBeat, Stryker currently has an average rating of "Moderate Buy" and an average target price of $421.90.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.